Lipfendra
enlicitide
Cholesterol / PCSK92026
Process development · Bioprocess modeling · Leadership
Kevin E. Stone
I build process models from lab data, and I lead the scientists who use them to make decisions on Merck's biologics pipeline.
01
About
Over the past decade at Merck I've contributed to eight approved medicines. I started as a reaction engineer on doravirine, carrying steps from development through filing and launch, and over the years added high-throughput experimentation, kinetic modeling, Bayesian optimization, and machine learning to how I work.
Today I lead a team of 10 bioprocess modeling scientists working with biologics process development on cell culture models, bioreactor scale-up and scale-down, chromatography, and filtration. I still write a lot of the code myself, including obsidian and GARNET.
Read the longer version
02
Pipeline
Medicines I have contributed to
My experimental work supports the filings and commercial processes of each of these medicines.
Idvynso
doravirine · islatravir
HIV-12026
Lyfnua
gefapixant
Chronic cough2022
Welireg
belzutifan
Oncology2021
Lagevrio
molnupiravir
COVID-19 antiviral2021
Delstrigo
doravirine · lamivudine · tenofovir
HIV-12018
Pifeltro
doravirine
HIV-12018
Gardasil 9
9-valent HPV vaccine
Cancer prevention
03
Now
- Building a full-service bioprocess modeling group for biologics drug-substance development.
- Using models to guide upstream process characterization and bioreactor scale-up, with new work in scale-down and filtration modeling.
- At the piano, still working through Liszt.
04
Contact
Get in
touch.
Email is the best way to reach me.